Home
Projects
Galvus (vildagliptin) - DPP-IV Inhibitor / Oral
Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent
Print
Current estimates indicate that worldwide about 170 million people suffer from diabetes, which is projected to reach 366 million by 2030.
«Back
Return to Profile
Home
|
New On This Site
|
Products & Services
|
Company A-Z
|
Industry Projects
|
White Papers
|
Jobs & Careers
|
Press Releases
|
Events & Exhibitions
|
Newsletter
|
Organisations
|
About Us
|
Contact Us
|
Advertise With Us
|
Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area
For every phase of your drug development
Search